BNP PARIBAS ARBITRAGE, SA
Position in MRVI — Maravai Lifesciences Holdings, Inc.
CIK 1166588
NEW YORK, NY
Position in MRVI
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$4,948,082
+$4,723,740 QoQ
Shares Held
792,962
+900.3% QoQ
Ownership
0.305%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#41
of 177 holders
Holding Since
Sep 2022
8 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in MRVI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026BNP PARIBAS ARBITRAGE, SA holds $3,275,701,265 across 414 Biotechnology names. MRVI ranks #73 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MRNA |
Moderna, Inc.
|
4,377,120 | $306,529,713 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
399,847 | $249,320,598 | |
| 3 | ARGX |
Argenx SE
|
157,958 | $146,548,693 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
262,258 | $130,271,416 | |
| 5 | BNTX |
BioNTech SE
|
1,319,517 | $122,781,056 | |
| 6 | RVMD |
Revolution Medicines, Inc.
|
552,710 | $103,511,528 | |
| 7 | ORKA |
Oruka Therapeutics, Inc.
|
1,079,015 | $102,689,857 | |
| 8 | BBIO |
BridgeBio Pharma, Inc.
|
1,155,442 | $86,057,320 |
All Filings in MRVI
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $4,948,082 | 792,962 | Shares | Defined | 2026-08-13 | |
| 2026-03-31 | $224,342 | 79,273 | Shares | Defined | 2026-05-12 | |
| 2025-12-31 | $365,966 | 112,605 | Shares | Defined | 2026-02-10 | |
| 2025-09-30 | $95,691 | 33,342 | Shares | Defined | 2025-11-13 | |
| 2025-06-30 | $303,327 | 125,862 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $299,459 | 135,502 | Shares | Defined | 2025-05-14 | |
| 2024-12-31 | $362,114 | 66,443 | Shares | Defined | 2025-02-14 | |
| 2022-09-30 | $374,754 | 14,679 | Shares | Defined | 2022-11-16 | |
| No filing history on record for this holder in this stock. | ||||||